A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pancreatic Cancer
- Sponsor
- National Cancer Center, Korea
- Enrollment
- 238
- Locations
- 1
- Primary Endpoint
- median survival
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
- Based on the literature, the pancreatic cancer treatment predictor biomarker, which is used in the domestic clinical field, is actually applied to the pancreatic cancer patient cohort of the National Cancer Center.
- To systematically prospectively identify prospective treatment response biomarkers for Pancreatic Cancer Cohort in the National Cancer Center
Detailed Description
1. Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd, MSI, Tumor Ag and etc. on Cancer sample 2. Collect data of Biomarker for pancreatic cancer 3. Compare with Big data and Cohort study in National cancer center 4. The number of subjects is changed by statistical consideration. 218-\>238
Investigators
Sang Myung Woo
Chief, Senior Scientist
National Cancer Center, Korea
Eligibility Criteria
Inclusion Criteria
- •Pathologically Confirmed Pancreatic Cancer Patients
Exclusion Criteria
- •Subjects who do not agree with the study
Outcomes
Primary Outcomes
median survival
Time Frame: 5 years
The length of time from either the date of diagnosis or the start of treatment for a disease,the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse
progressive-free survival
Time Frame: 5 years
The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse